RT Journal Article
SR Electronic
T1 Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.29.21259693
DO 10.1101/2021.06.29.21259693
A1 Emily Toscano-Guerra
A1 Mónica Martínez Gallo
A1 Iria Arrese-Muñoz
A1 Anna Giné
A1 Noelia Díaz
A1 Pablo Gabriel-Medina
A1 Mar Riveiro-Barciela
A1 Moisés Labrador-Horrillo
A1 Fernando Martinez-Valle
A1 Manuel Hernández-González
A1 Ricardo Pujol Borrell
A1 Francisco Rodríguez-Frias
A1 Roser Ferrer
A1 Timothy M. Thomson
A1 Rosanna Paciucci
YR 2021
UL http://medrxiv.org/content/early/2021/07/01/2021.06.29.21259693.abstract
AB Infection with SARS-CoV-2 portends a broad range of outcomes, from a majority of asymptomatic cases or mild clinical courses to a lethal disease. Robust correlates of severe COVID-19 include old age, male sex, poverty and co-morbidities such as obesity, diabetes or cardiovascular disease. A precise knowledge is still lacking of the molecular and biological mechanisms that may explain the association of severe disease with male sex. Here, we show that testosterone trajectories are highly accurate individual predictors (AUC of ROC = 0.928, p < 0.0001) of survival in male COVID-19 patients. Longitudinal determinations of blood levels of luteinizing hormone (LH) and androstenedione suggest an early modest inhibition of the central LH-androgen biosynthesis axis in a majority of patients, followed by either full recovery in survivors or a peripheral failure in lethal cases. Moreover, failure to reinstate physiological testosterone levels was associated with evidence of impaired T helper differentiation and decrease of non-classical monocytes. The strong association of recovery or failure to reinstate testosterone levels with survival or death from COVID-19 in male patients is suggestive of a significant role of testosterone status in the immune responses to COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by grants from the Ministerio de Ciencia e Innovacion (RTI2018-096055-B-I00), Consejo Superior de Investigaciones Cientificas COVID-19 Research Fund (CSIC-COV19-006, CSIC-COV19-201), Agencia de Gestio Ajuts Universitaris i de Recerca (2020PANDE00048 and 2017SGR 1411 GRC), Plan Nacional de I+D (PID-107139RB-C21) and Instituto Nacional de la Salud Carlos III (PI18/00346 and COVID-19_00416).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was performed with surplus serum samples from routinely tested COVID-19 patients, following a protocol reviewed and approved by the Hospital Vall d'Hebron Institutional Review Board (Medical Research Ethics Committee, protocol number PR(AG)329-2020). Immunophenotyping studies of peripheral blood cells underwent a separate review and approval process (protocol number PR(AG)242/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data described in our manuscript will be made available to interested researchers upon request within appropriate collaboration settings.